Products for Research Use Only

Brilaroxazine

CAT: 0804-HY-109112-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109112-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA) /serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].
CAS Number
1239729-06-6
Product Name Alternative
RP5063
UNSPSC
12352005
Target
5-HT Receptor; Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/brilaroxazine.html
Concentration
10mM
Purity
98.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NC2=CC(OCCCCN3CCN(C(C=CC=C4Cl)=C4Cl)CC3)=CC=C2OC1
Molecular Formula
C22H25Cl2N3O3
Molecular Weight
450.36
References & Citations
[1]Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits|[2]Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.Eur J Pharmacol. 2018 May 15;827:159-166.|[3]L. Bhat, et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
5-HT1 Receptor;5-HT2 Receptor;5-HT7 Receptor; D2 Receptor; D3 Receptor; D4 Receptor; mLAG-3; MUC3; α-1 microglobulin

Chemical Information

Brilaroxazine

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.

CAS Number1239729-06-6
PubChem CID46861612
IUPAC Name6-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4H-1,4-benzoxazin-3-one
Molecular FormulaC22H25Cl2N3O3
Molecular Weight450.4
XLogP4.4
Topological Polar Surface Area54
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count7
Heavy Atom Count30
Formal Charge0
Complexity562
SMILES
C1CN(CCN1CCCCOC2=CC3=C(C=C2)OCC(=O)N3)C4=C(C(=CC=C4)Cl)Cl
InChI
InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28)
InChIKey
PMKMNTBZJOXTJW-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Brilaroxazine
CAS: 1239729-06-6
CID: 46861612
Formula: C22H25Cl2N3O3
MW: 450.4
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight450.4
XLogP34.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count7
Exact Mass449.1272971
Monoisotopic Mass449.1272971
Topological Polar Surface Area54 Ų
Heavy Atom Count30
Formal Charge0
Complexity562
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Popular Products